metricas
covid
Buscar en
Clínica e Investigación en Ginecología y Obstetricia
Toda la web
Inicio Clínica e Investigación en Ginecología y Obstetricia Tratamiento hormonal sustitutivo de la menopausia y mortalidad
Journal Information
Vol. 31. Issue 3.
Pages 85-92 (January 2004)
Share
Share
Download PDF
More article options
Vol. 31. Issue 3.
Pages 85-92 (January 2004)
Full text access
Tratamiento hormonal sustitutivo de la menopausia y mortalidad
Visits
3895
J. López-Olmos
Unidad de Menopausia. Servicio de Ginecología. Hospital Arnau de Vilanova. Valencia. España.
This item has received
Article information
Resumen

Presentamos 5 casos de mortalidad con THS (0,61%) en una serie personal de 810 mujeres tratadas durante 8 años.

La edad media fue 58,2 años (rango,52-68 años). La edad media a la menopausia fue de 47,6 años (ran-go,43-54 años). El tiempo medio de THS fue de 6,8años (rango 4-9 años).

Los procesos y su causa de muerte fueron:una insuficiencia respiratoria por pancreatitis aguda necrohemorrágica; un cáncer de estómago con metástasis múltiples; un cáncer de pulmón con metástasis óseas; una pancitopenia grave y shock secundarios a metotrexato,y un cáncer de mama con metástasis múltiples. Este último caso es el único que podemos relacionar con el THS.

Revisamos la mortalidad con THS,y en particular su riesgo en el cáncer de mama.

Abstract

We present 5 cases of mortality with HRT (0.61%) in a personal series of 810 women treated over 8 years.

The mean age was 58.2 years (range, 52-68). The mean age at the menopause was 47.6 years (range, 43-54). The mean duration of treatment was (6.8) years (range, 4-9). The causes of death were: acute respiratory failure following acute necrohaemorrhagic pancreatitis; stomach cancer with multiple metastases; lung cancer with bone metesteses; severe pancytopenia and shock secondary to Metotrexate treatment; and a breast cancer with multiple metasteses. The last case is the only one that we can relate to HRT. We reviewed mortality with HRT particularly related to breast cancer risk.

Full text is only aviable in PDF
Bibliografía
[1.]
B.G. Wren, J.A. Eden.
Hormone replacement therapy: a review, part I.
Fem Patient, 4 (1994), pp. 5-16
[2.]
ACOG Technical Bulletin number 166, 1992..
Int J Gynecol Obstet, 41 (1993), pp. 194-202
[3.]
B.G. Wren, J.A. Eden.
Hormone replacement therapy: a review, part II.
Fem Patient, 4 (1994), pp. 5-14
[4.]
D.M. Witt, T.R. Lousberg.
Controversies surrounding estrogen use in postmenopausal women.
Ann Pharmacother, 31 (1997), pp. 745-755
[5.]
K.A. Matthews, L.H. Kuller, R.R. Wing, E.N. Mellahan, P. Plantinga.
Prior to use of estrogen replacement therapy are users healthier than nonusers?.
Am J Epidemiol, 143 (1996), pp. 971-978
[6.]
N.F. Col, M.H. Eckman, R.H. Karas, S.G. Pauker, R.J. Goldberg, E.M. Ross, et al.
Patient-specific decisions about hormone replacement therapy in postmenopausal women.
JAMA, 277 (1997), pp. 1140-1147
[7.]
E. Hemminki, K. McPherson.
Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials.
BMJ, 315 (1997), pp. 149-153
[8.]
M.A. Khan, M.W. Liu, D. Singh, A. Pal, F.L. Chio, D. Lawson.
Am J Cardiol, 86 (2000), pp. 330-333
[9.]
S. Hulley, C. Furberg, E. Barrett-Connor, J. Cauley, D. Grady, W. Haskell, al et, the HERS Research Group. for.
Non cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study. Follow-up (HERS II.
JAMA, 288 (2002), pp. 58-66
[10.]
L. Bergkvist, H.O. Adami, I. Persson, R. Bergström, U.B. Krusemo.
Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy.
Am J Epidemiol, 130 (1989), pp. 221-228
[11.]
D.M. Strickland, RD Jr Gambrell, C.A. Butzin, K. Strickland.
The relationship between breast cancer survival and prior postmenopausal estrogen use.
Obstet Gynecol, 80 (1992), pp. 400-404
[12.]
J.L. Stanford, N.S. Weiss, L.F. Voigt, J.R. Daling, L.A. Habel, M.A. Rossing.
Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
JAMA, 274 (1995), pp. 137-142
[13.]
G.A. Colditz, S.E. Hankinson, D.J. Hunter, W.C. Willet, J.E. Manson, M.J. Stampfer, et al.
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
N Engl J Med, 332 (1995), pp. 1589-1593
[14.]
P. Kennemans, F. Scheele, C.W. Burger.
Hormone replacement therapy and breast cancer morbidity, mortality and recurrence.
Eur J Obstet Gynecol Reprod Biol, 71 (1997), pp. 199-203
[15.]
K. Hunt, M. Vessey, K. McPherson, M. Coleman.
Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy.
Br J Obstet Gynecol, 94 (1987), pp. 620-635
[16.]
M.H. Criqui, L. Suarel, E. Barrett-Connor, J. McPhillips, D.L. Wingard, C. Garland.
Postmenopausal estrogen use and mortality. Results from a prospective study in a defined homogeneous community.
Am J Epidemiol, 128 (1988), pp. 606-614
[17.]
D. Grady, S.M. Rubin, D.B. Petitti, C.S. Fox, D. Black, B. Ettinger, et al.
Hormone therapy to prevent disease and prolong life in postmenopausal women.
Annals Inter Med, 117 (1992), pp. 1016-1037
[18.]
A.R. Folsom, P.J. Mink, T.A. Sellers, C.P. Hong, W. Zheng, J.D. Potter.
Hormone replacement therapy and morbidity and mortality in a prospective study of postmenopausal women.
Am J Public Health, 85 (1995), pp. 1128-1132
[19.]
I. Persson, J. Yuen, L. Bergkvist, C. Schairer.
Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy. Long-term follow-up of a Swedish cohort.
[20.]
B. Ettinger, G.D. Friedman, T. Bush, CP Jr. Quesenberry.
Reduced mortality associated with long-term postmenopausal estrogen therapy.
Obstet Gynecol, 87 (1996), pp. 6-12
[21.]
F. Grodstein, M.J. Stampfer, G.A. Colditz, W.C. Willet, J.E. Manson, M. Joffe, et al.
Postmenopausal hormone therapy and mortality.
N Engl J Med, 336 (1997), pp. 1769-1775
[22.]
J.A. Cauley, D.G. Seeley, W.S. Browner, K. Ensrud, L.H. Huller, R.C. Lipschutz, et al.
Estrogen replacement therapy and mortality among older women. (The study of osteoporotic fractures.
Arch Intern Med, 157 (1997), pp. 2181-2187
[23.]
S. Panico, R. Galasso, E. Celentano, A.V. Ciardullo, L. Frova, R. Cadocaccia, et al.
Large-scale hormone replacement therapy and life expectancy: results from an international comparison among European and North American populations.
Am J Public Health, 90 (2000), pp. 1397-1402
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos